Takeda Pharmaceutical Company Limited - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
TAK New York 2830 www.takeda.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Takeda Pharmaceutical Company Limited

Disease Clearance Data Might Change The Case For Investing In Takeda (TSE:4502) - Oct 20th, 2026 10:09 am
Asian Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - Oct 20th, 2026 8:40 am
Merck KGaA bets on RNAi with $1.3B Silence buyout - Oct 19th, 2026 7:59 am
First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication - Oct 19th, 2026 3:30 am
Cathie Wood-Backed Biotech IPO Pops in Debut - Oct 15th, 2026 11:38 am
Asian Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading - Oct 15th, 2026 8:40 am
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1 - Oct 14th, 2026 6:30 pm
Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026 - Oct 14th, 2026 6:00 am
SLS Stock Jumps Overnight: Retail Sees Big Pharma Buyout Clues In 'M&A Negotiation Lounge' Booth At ASH - Oct 11th, 2026 7:22 pm
eClinical Solutions Turns Clinical Data Intelligence Into Action at ENGAGE 2026 - Oct 8th, 2026 11:41 am
Asian Equities Traded in the US as American Depositary Receipts Tumble in Wednesday Trading - Oct 7th, 2026 8:40 am
Biopharma's Leapfrog Moment: The Launch of the Digital CMC Consortium - Oct 6th, 2026 4:00 am
Takeda (TSE:4502) Stock Looks Below Fair Value Even After A 120% Run - Oct 1st, 2026 1:08 pm
Corus International Receives $6.4 Million Grant From Takeda to Reduce Climate-Related Health Risks in Nepal - Oct 1st, 2026 9:43 am
Will Zasocitinib’s Phase 3 Outperformance Reshape Takeda Pharmaceutical's (TSE:4502) Immunology-Driven Pipeline Narrative - Oct 1st, 2026 9:08 am
Takeda Pharmaceutical (TSE:4502) Could Be 13% Undervalued On Strong Phase 3 Psoriasis Data - Sep 30th, 2026 2:09 pm
Asian Equities Traded in the US as American Depositary Receipts Rise Modestly in Wednesday Trading - Sep 30th, 2026 8:49 am
Takeda Reports New Psoriasis Treatment Outperformed Competitor in Phase 3 Trial - Sep 30th, 2026 2:12 am
Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill - Sep 29th, 2026 11:00 pm
KROS Begins Dosing in Phase II Study With Rinvatercept in DMD - Sep 29th, 2026 7:17 am